Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL)

被引：8
|
作者：
Dondorf, Sabine
Schrader, Alexandra [1 ]
Herling, Marco
机构：
[1] Univ Cologne, Lab Lymphocyte Signaling & Oncoproteome, Dept Internal Med 1, Ctr Integrated Oncol CIO Koln Bonn, D-50931 Cologne, Germany
来源：
JOURNAL OF BIOLOGICAL CHEMISTRY | 2015年 / 290卷 / 16期
关键词：
INHIBITORS;
D O I：
10.1074/jbc.L115.644641
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
6
引用
收藏
页码：10568 / 10569
页数：2
相关论文
共 50 条
  • [41] Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694
    Zhong, Yiming
    Dong, Shuai
    Strattan, Ethan
    Ren, Li
    Butchar, Jonathan P.
    Thornton, Kelsey
    Mishra, Anjali
    Porcu, Pierluigi
    Bradshaw, J. Michael
    Bisconte, Angelina
    Owens, Timothy D.
    Verner, Erik
    Brameld, Ken A.
    Funk, Jens Oliver
    Hill, Ronald J.
    Johnson, Amy J.
    Dubovsky, Jason A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (10) : 5960 - 5978
  • [42] T-cell prolymphocytic leukemia - an update
    Hopfinger, G.
    Herling, M.
    Oncology Research and Treatment, 2015, 38 : 257 - 257
  • [43] Polytypic T-cell prolymphocytic leukemia
    Ames, Erik
    Silva, Oscar
    BLOOD, 2021, 137 (15) : 2125 - 2125
  • [44] Multiple Tumors in a Patient with Interleukin-2-Inducible T-Cell Kinase Deficiency: A Case Report
    Di Filippo, Michela
    Tallone, Ramona
    Muraca, Monica
    Pelanconi, Lisa
    Faravelli, Francesca
    Capra, Valeria
    De Marco, Patrizia
    Ognibene, Marzia
    Baldassari, Simona
    Terranova, Paola
    Livellara, Virginia
    Vellone, Valerio Gaetano
    Miano, Maurizio
    Amoroso, Loredana
    Beccaria, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
  • [45] Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma
    Khodadoust, Michael S.
    Feldman, Tatyana A.
    Yoon, Dok Hyun
    Yannakou, Costas K.
    Radeski, Dejan
    Kim, Youn H.
    Mehta-Shah, Neha
    Khot, Amit
    Wilcox, Ryan A.
    Kim, Won Seog
    Horwitz, Steven M.
    Buggy, Joseph J.
    Hotson, Andrew
    Hill, Craig M.
    Munneke, Brian
    Mahabhashyam, Suresh
    Miller, Richard A.
    Janc, James W.
    Mobasher, Mehrdad
    BLOOD, 2020, 136
  • [46] Interleukin-2-Inducible T-Cell Kinase Deficiency-New Patients, New Insight?
    Ghosh, Sujal
    Drexler, Ingo
    Bhatia, Sanil
    Gennery, Andrew R.
    Borkhardt, Arndt
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [47] Inhibition of IL2-Inducible T-Cell Kinase (ITK)-Mediated Chemoresistance By Ibrutinib in T-Cell Lymphoproliferative Disorders
    Wang, Tianjiao
    Lu, Ye
    Polk, Avery
    Zamalloa, Carlos Murga
    Wilcox, Ryan A.
    BLOOD, 2015, 126 (23)
  • [48] CDK9 Inhibition with LDC526 Is an Effective Treatment for T-Cell Prolymphocytic Leukemia (T-PLL) in Vitro
    Johansson, Patricia
    Habenberger, Peter
    Klein-Hitpass, Ludger
    Duehrsen, Ulrich
    Kuppers, Ralf
    Schultz-Fademrecht, Carsten
    Choidas, Axel
    Durig, Jan
    BLOOD, 2017, 130
  • [49] “T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach”
    Carlos A Tirado
    Phillip Starshak
    Paul Delgado
    Nagesh Rao
    Experimental Hematology & Oncology, 1 (1)
  • [50] T-Cell Prolymphocytic Leukemia (T-PLL) with t(X;14)(q28; q11.2): A Report of 17 Cases
    Hu, Zhihong
    Xu, Mina
    Yuan, Ji
    Peker, Deniz
    Shao, Lina
    Rios, Adan
    Medeiros, L. Jeffrey
    Hu, Shimin
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 844 - 844
12345